drugset
Drugs / PALUPIPRANT
last change Sep 2021 re-read 3 minutes ago

PALUPIPRANT

also known as E7046 · ER 886046

Small molecule

Developed for
neoplasm
Investigated by
Adlai Nortye Biopharma Co., Ltd. · Eisai Inc.

Trials 2

today NCT03152370 · Ph 1 NCT02540291 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03152370 May 2017 → Aug 2021 — Adlai Nortye Biopharma Co., Ltd. Completed No outcome recorded
Phase 1 NCT02540291 Jul 2015 → Feb 2018 neoplasm Eisai Inc. Terminated No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2018-01-19 Eisai Inc. EISAI ENTERS INTO LICENSING AGREEMENT WITH ADLAI NORTYE FOR POTENTIAL ANTICANCER AGENT E7046 (PROSTAGLANDIN E2 RECEPTOR TYPE 4 ANTAGONIST) eisai.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as PALUPIPRANT ChEMBL registry synonym — accepted as the source's own label CHEMBL3670685 ↗
Known as E7046 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03152370 ↗
1

NCT02540291 ↗
Known as ER 886046 ChEMBL registry synonym — accepted as the source's own label CHEMBL3670685 ↗
Action Inhibit “E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune...” PMID 32554609 ↗ Jun 2020
Modality Small molecule “E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune...” PMID 32554609 ↗ Jun 2020
Route Oral “E7046 was administered orally once-daily in sequential escalating dose cohorts (125, 250, 500, and 750 mg) with ≥6 patients per cohort.” PMID 32554609 ↗ Jun 2020